Tafasitamab Approval Expands Chemotherapy-Free Treatment Options for R/R Follicular Lymphoma: Christina Poh, MD

Christina Poh, MD, of City of Hope National Medical Center, highlights the benefit of tafasitamab in improving progression-free survival for heavily pretreated patients with relapsed or refractory (R/R) follicular lymphoma.